Human Chorionic Gonadotropin Market - Forecast(2021 - 2026)

Report Code: HCR 19787 Report Format: PDF + Excel (Delivery in 48 Hrs)
Human Chorionic Gonadotropin Market Overview
Human Chorionic Gonadotropin Market size is forecast to reach $1.18 billion by 2025, growing at a CAGR of 6.91% during the forecast period 2020-2025. Human chorionic gonadotropin (hCG) is a hormone produced by the placenta after implantation. Gonadotropins usually consist of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The presence of hCG is detected in some pregnancy tests, for example, HCG pregnancy strip tests. Some cancerous tumors produce hCG hormone; therefore, elevated levels measured when the patient is not pregnant may lead to a cancer diagnosis and, if high enough, paraneoplastic syndromes, however, it is not known whether this production is a contributing cause, or an effect of carcinogenesis. Rise in demand for infertility treatment products and services, rising incidences of male hypogonadism among the aged population and increase in awareness about infertility treatment are major factors that are driving the market growth in recent years. In addition, major developments by key market players like Ferring and Sanzyme are other factors driving the growth of the market.
 
Report Coverage
The report: “Human Chorionic Gonadotropin Market Forecast (2020-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Human Chorionic Gonadotropin Market. 

By Technology: Natural Source Extraction, Recombinant Technology
By Therapeutic Area: Female Infertility Treatment, Oligospermic Treatment, Male Hypogonadism
By End User: Fertility Clinic, Research institutes, Others
By Geography: North America, Europe, Asia-Pacific, RoW.

Key Takeaways
  • North America dominated the Human Chorionic Gonadotropin Market in the year 2019 owing to rising prevalence of infertility among both genders of the adult population, increasing healthcare affordability of the majority population and government initiatives to support technological advancements. The Human Chorionic Gonadotropin Market scope for different regions will be provided in the final report.
  • Increase in number of local fertility clinics, presence of advanced technological treatments of infertility, technological advancements in Gonadotropin Market and favorable government policies for fertility provision services have helped in significant growth of Human Chorionic Gonadotropin Market. Increasing investments for economical and cost effective infertility treatment by key market players and various government agencies in upcoming years is estimated to drive the industry growth during the forecast period 2020-2025.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Human Chorionic Gonadotropin Market report.
  • Side effects of Human Chorionic Gonadotropin (hCG) is anticipated to hamper the market growth of the Human Chorionic Gonadotropin Industry.

Technology - Segment Analysis
Natural Source Extraction held the largest share in the technology segment of Human Chorionic Gonadotropin Market in 2019 and is estimated to grow at a CAGR of 5.29% during the forecast period 2020-2025. Factors that contribute to the growth of this segment are the increasing applications of nature sources extracted gonadotropin in the treatment of infertility disorders among men and women, greater preference by key market players for extracting gonadotropin from natural sources and application in other medical conditions such as cryptorchidism. Recombinant Technology held the second largest share in the market. Recombinant FSH (rFSH) has been shown to be safe and effective in the treatment of fertility disorders. In comparison with the urinary gonadotropin products, human menopausal gonadotropins (HMG), and urinary follitropins (uFSH), rFSH is more potent and better tolerated by patients. Recombinant Technology segment is set to be the fastest growing segment and is set to register the highest CAGR during the forecast period 2020-2025, owing to major investments in technology and innovation for gonadotropin products by key market players.

Therapeutic Area - Segment Analysis
Female Infertility Treatment segment holds the major share in the application segment of Human Chorionic Gonadotropin Market in 2019. About ten in 100 (6.1 million) women in the U.S. aged 25–44 have difficulty becoming pregnant or staying pregnant, according to the Centers for Disease Control and Prevention. In addition, growing number of fertility clinics and gynecological centers have helped in the market growth of this segment. Male Hypogonadism held the second largest share in the market, owing to higher prevalence of chronic diseases which in turn leads to lower testosterone levels among the middle aged men. Female Infertility segment is forecast to continue growing at the fastest rate with the highest CAGR during the forecast period 2020-2025, owing to growing trends in infertility treatment among woman and upgrading lifestyle standards.

Geography - Segment Analysis
North America dominates the geography segment of Human Chorionic Gonadotropin Market with a share of more than 40.7% in 2019, followed by Europe. Growing prevalence of infertility among the adult population, increasing average income of the masses and government initiatives to support technological advancements have helped in the growth of Human Chorionic Gonadotropin Market in this region. Europe held the second place in the geography segment share of the market, owing to increasing health awareness among the masses and technological improvements of infertility treatment methods.
However, Asia-Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025. This is owing to growth of the IVF market, entry of new players in the region, increasing incidences of female infertility and growing prevalence of hypogonadism among the geriatric population.

Drivers – Human Chorionic Gonadotropin Market

  • Rising incidences of male hypogonadism among the aged population
Hypogonadism affects an estimated 4 to 5 million men in the U.S., and although it may occur in men at any age, low testosterone levels are especially common in older males. More than 60% of men over age 65 have free testosterone levels below the normal values of men aged 30 to 35. With the growing population at present, combined with increasing prevalence of chronic diseases among a majority of the population, the numbers are anticipated to witness a great surge. As a result, this is set to drive the market growth during the forecast period 2020-2025.

  • Increase in number of local fertility clinics
The last decade saw the advent of fertility clinics in all regions, mostly locally. Recent publicity given to developments such as gamete intra fallopian transfer (GIFT) and IVF have further increased the demand for infertility treatment. Based on CDC’s 2017 Fertility Clinic Success Rates Report, there were 284,385, infertility treatments performed at 448 reporting clinics in the U.S. during 2017, resulting in 68,908 live births (deliveries of one or more living infants) and 78,052 live born infants. With such large numbers, the market is poised to see significant growth during the forecast period 2020-2025.

Challenges – Human Chorionic Gonadotropin Market

  • Side effects of Human Chorionic Gonadotropin (hCG)
Common side effects of Human Chorionic Gonadotropin (hCG) include headache, irritability, restlessness, fatigue, depression, swelling in the feet, ankles, lowers legs, or hands and appearance of female breasts in men. This creates a negative impact on the demand of hCG among end users. Thus, it is anticipated to hamper the market growth during the forecast period 2020-2025.

Human Chorionic Gonadotropin Industry Outlook
Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Human Chorionic Gonadotropin Market. In 2019, Human Chorionic Gonadotropin Market share is consolidated by the top players present in the market. Human Chorionic Gonadotropin Market top 10 companies are Bristol Myers Squibb Company, Merck & Co., Inc., Ferring Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Lee BioSolutions Inc., LUPIN, Sanzyme, Scripps Laboratories and Cigna among others.

Acquisitions/Product Launches
  • In January 2019, Ferring acquired exclusive U.S. commercialization rights for generic Ganirelix Acetate Injection for the prevention of premature ovulation in women undergoing fertility treatment.
  • In June 2018, Sanzyme entered into an agreement with Inolife for Gonadotropin Kinetics and Bio-Equivalence Validation.
  • In May 2020, Tolmar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its drug application for FENSOLVI® (leuprolide acetate) for injectable suspension for the treatment of pediatric patients two years of age and older with central (gonadotropin-dependent) precocious puberty (CPP).

1. Human Chorionic Gonadotropin Market Overview
    1.1 Definitions and Scope
2. Human Chorionic Gonadotropin Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Technology
    2.3 Key trends by Therapeutic Area 
    2.4 Key trends by Geography
3. Human Chorionic Gonadotropin Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Human Chorionic Gonadotropin Market - Startup Companies Scenario (Premium)
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Human Chorionic Gonadotropin Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Human Chorionic Gonadotropin Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Human Chorionic Gonadotropin Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Human Chorionic Gonadotropin Market – By Technology (Market Size –$Million/$Billion)
    8.1 Natural Source Extraction
    8.2 Recombinant Technology
9. Human Chorionic Gonadotropin Market – By Therapeutic Area (Market Size –$Million/$Billion)
    9.1 Female Infertility Treatment
    9.2 Oligospermic Treatment
    9.3 Male Hypogonadism
10. Human Chorionic Gonadotropin Market – By End User (Market Size –$Million/$Billion)
    10.1 Fertility Clinic
    10.2 Research Institute
    10.3 Others
11. Human Chorionic Gonadotropin Market – By Geography (Market Size –$Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 U.K.
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia-Pacific
    11.4 Rest of the World
        11.4.1 Middle East
        11.4.2 Africa
        11.4.3 South America
12. Human Chorionic Gonadotropin Market - Entropy
13. Human Chorionic Gonadotropin Market – Industry/Segment Competition Landscape (Premium) 
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Human Chorionic Gonadotropin Market – Key Company List by Country Premium (Premium)
15. Human Chorionic Gonadotropin Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global Human Chorionic Gonadotropin Market, By Technology Market 2019-2024 ($M)
1.1 Natural Source Extraction Market 2019-2024 ($M) - Global Industry Research
1.2 Recombinant Technology Market 2019-2024 ($M) - Global Industry Research
2.Global Human Chorionic Gonadotropin Market, By Therapeutic Area Market 2019-2024 ($M)
2.1 Female Infertility Treatment Market 2019-2024 ($M) - Global Industry Research
2.2 Oligospermic Treatment Market 2019-2024 ($M) - Global Industry Research
2.3 Male Hypogonadism Market 2019-2024 ($M) - Global Industry Research
3.Global Human Chorionic Gonadotropin Market, By End User Market 2019-2024 ($M)
3.1 Fertility Clinic Market 2019-2024 ($M) - Global Industry Research
3.2 Research Institute Market 2019-2024 ($M) - Global Industry Research
4.Global Human Chorionic Gonadotropin Market, By Technology Market 2019-2024 (Volume/Units)
4.1 Natural Source Extraction Market 2019-2024 (Volume/Units) - Global Industry Research
4.2 Recombinant Technology Market 2019-2024 (Volume/Units) - Global Industry Research
5.Global Human Chorionic Gonadotropin Market, By Therapeutic Area Market 2019-2024 (Volume/Units)
5.1 Female Infertility Treatment Market 2019-2024 (Volume/Units) - Global Industry Research
5.2 Oligospermic Treatment Market 2019-2024 (Volume/Units) - Global Industry Research
5.3 Male Hypogonadism Market 2019-2024 (Volume/Units) - Global Industry Research
6.Global Human Chorionic Gonadotropin Market, By End User Market 2019-2024 (Volume/Units)
6.1 Fertility Clinic Market 2019-2024 (Volume/Units) - Global Industry Research
6.2 Research Institute Market 2019-2024 (Volume/Units) - Global Industry Research
7.North America Human Chorionic Gonadotropin Market, By Technology Market 2019-2024 ($M)
7.1 Natural Source Extraction Market 2019-2024 ($M) - Regional Industry Research
7.2 Recombinant Technology Market 2019-2024 ($M) - Regional Industry Research
8.North America Human Chorionic Gonadotropin Market, By Therapeutic Area Market 2019-2024 ($M)
8.1 Female Infertility Treatment Market 2019-2024 ($M) - Regional Industry Research
8.2 Oligospermic Treatment Market 2019-2024 ($M) - Regional Industry Research
8.3 Male Hypogonadism Market 2019-2024 ($M) - Regional Industry Research
9.North America Human Chorionic Gonadotropin Market, By End User Market 2019-2024 ($M)
9.1 Fertility Clinic Market 2019-2024 ($M) - Regional Industry Research
9.2 Research Institute Market 2019-2024 ($M) - Regional Industry Research
10.South America Human Chorionic Gonadotropin Market, By Technology Market 2019-2024 ($M)
10.1 Natural Source Extraction Market 2019-2024 ($M) - Regional Industry Research
10.2 Recombinant Technology Market 2019-2024 ($M) - Regional Industry Research
11.South America Human Chorionic Gonadotropin Market, By Therapeutic Area Market 2019-2024 ($M)
11.1 Female Infertility Treatment Market 2019-2024 ($M) - Regional Industry Research
11.2 Oligospermic Treatment Market 2019-2024 ($M) - Regional Industry Research
11.3 Male Hypogonadism Market 2019-2024 ($M) - Regional Industry Research
12.South America Human Chorionic Gonadotropin Market, By End User Market 2019-2024 ($M)
12.1 Fertility Clinic Market 2019-2024 ($M) - Regional Industry Research
12.2 Research Institute Market 2019-2024 ($M) - Regional Industry Research
13.Europe Human Chorionic Gonadotropin Market, By Technology Market 2019-2024 ($M)
13.1 Natural Source Extraction Market 2019-2024 ($M) - Regional Industry Research
13.2 Recombinant Technology Market 2019-2024 ($M) - Regional Industry Research
14.Europe Human Chorionic Gonadotropin Market, By Therapeutic Area Market 2019-2024 ($M)
14.1 Female Infertility Treatment Market 2019-2024 ($M) - Regional Industry Research
14.2 Oligospermic Treatment Market 2019-2024 ($M) - Regional Industry Research
14.3 Male Hypogonadism Market 2019-2024 ($M) - Regional Industry Research
15.Europe Human Chorionic Gonadotropin Market, By End User Market 2019-2024 ($M)
15.1 Fertility Clinic Market 2019-2024 ($M) - Regional Industry Research
15.2 Research Institute Market 2019-2024 ($M) - Regional Industry Research
16.APAC Human Chorionic Gonadotropin Market, By Technology Market 2019-2024 ($M)
16.1 Natural Source Extraction Market 2019-2024 ($M) - Regional Industry Research
16.2 Recombinant Technology Market 2019-2024 ($M) - Regional Industry Research
17.APAC Human Chorionic Gonadotropin Market, By Therapeutic Area Market 2019-2024 ($M)
17.1 Female Infertility Treatment Market 2019-2024 ($M) - Regional Industry Research
17.2 Oligospermic Treatment Market 2019-2024 ($M) - Regional Industry Research
17.3 Male Hypogonadism Market 2019-2024 ($M) - Regional Industry Research
18.APAC Human Chorionic Gonadotropin Market, By End User Market 2019-2024 ($M)
18.1 Fertility Clinic Market 2019-2024 ($M) - Regional Industry Research
18.2 Research Institute Market 2019-2024 ($M) - Regional Industry Research
19.MENA Human Chorionic Gonadotropin Market, By Technology Market 2019-2024 ($M)
19.1 Natural Source Extraction Market 2019-2024 ($M) - Regional Industry Research
19.2 Recombinant Technology Market 2019-2024 ($M) - Regional Industry Research
20.MENA Human Chorionic Gonadotropin Market, By Therapeutic Area Market 2019-2024 ($M)
20.1 Female Infertility Treatment Market 2019-2024 ($M) - Regional Industry Research
20.2 Oligospermic Treatment Market 2019-2024 ($M) - Regional Industry Research
20.3 Male Hypogonadism Market 2019-2024 ($M) - Regional Industry Research
21.MENA Human Chorionic Gonadotropin Market, By End User Market 2019-2024 ($M)
21.1 Fertility Clinic Market 2019-2024 ($M) - Regional Industry Research
21.2 Research Institute Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
2.Canada Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
3.Mexico Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
4.Brazil Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
5.Argentina Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
6.Peru Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
7.Colombia Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
8.Chile Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
9.Rest of South America Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
10.UK Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
11.Germany Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
12.France Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
13.Italy Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
14.Spain Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
15.Rest of Europe Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
16.China Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
17.India Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
18.Japan Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
19.South Korea Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
20.South Africa Human Chorionic Gonadotropin Market Revenue, 2019-2024 ($M)
21.North America Human Chorionic Gonadotropin By Application
22.South America Human Chorionic Gonadotropin By Application
23.Europe Human Chorionic Gonadotropin By Application
24.APAC Human Chorionic Gonadotropin By Application
25.MENA Human Chorionic Gonadotropin By Application
26.Bristol Myers Squibb Company, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Ferring Pharmaceutical Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Merck Co , Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Fresenius Kabi Ag, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Cigna, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Sun Pharmaceutical Industry Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Lee Biosolutions Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Sanzyme, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Scripps Laboratory, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Lupin, Sales /Revenue, 2015-2018 ($Mn/$Bn)